RxDoctor Payments Data

Laurel Tucker, MD

Family Medicine · Houston, TXNPI 1528063633

Payments from drug & device makers

$6,171in general payments, 2019–2025

Across 348 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$835
  • Novo Nordisk$596
  • Lilly USA, LLC$534
  • Takeda Pharmaceuticals U.S.A., Inc.$352
  • Amarin Pharma, Inc.$341
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$6,165100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,171 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,286
Medicare patients
263
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$27,602
ProliaDenosumab12$20,388
JanuviaSitagliptin Phosphate19$19,839
SynthroidLevothyroxine Sodium116$7,584
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,900
Levothyroxine Sodium308$2,363
Tolterodine Tartrate ErTolterodine Tartrate36$2,338
Azelastine Hcl82$2,300
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,185
Atorvastatin Calcium242$2,075
Lisinopril209$1,552
Rosuvastatin Calcium153$1,504
ValacyclovirValacyclovir Hcl35$1,504
Omeprazole137$1,433
Ibandronate Sodium38$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$534$27,60227 claims
AmgenProlia$217$20,38812 claims
MerckJanuvia$211$19,83919 claims
AbbVieSynthroid$131$7,584116 claims
GSKShingrix$835$3,90018 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,363308 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →